335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22774 | Target tumour diameter of ? 2.0 cm (shortest axis) | Alain Hendlisz | pancreas | OncoSil Medical | PanCO | Trial closed | An open label, single arm pilot study of OncoSilTM, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 22610 | Adjuvant or neoadjuvant | Jean Klastersky | Breast | Institut Jules Bordet | Papaldo | Trial closed for recruitment | A phase II randomized study to verify the Papaldo's hypothesis : the effectiveness of a reduced dosing of G-CSF in chemotherapy-treated patients with a low to moderate risk of febrile neutropenia | jean.klastersky@hubruxelles.be | 2 | 2 | |
| 22743 | Metastatic hormono-sensitive prostate carcinoma | Thierry Gil | prostate | Unicancer | PEACE EORTC 1201 GETUG-AFU 21 | Trial closed for recruitment | A Prospective randomized phase III study of Androgen deprivation therapy with or without local radiotherapy with or without Abiraterone Acetate and Prednisone in patients with metastatic hormone-naïve prostate cancer | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22687 | Metastatic | François-Xavier Otte | prostate | UZ-Gent | PEACE V - STORM | Trial open for recruitment | PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | |
| 22825 | ER+/HER2- | Andrea Gombos | Breast | Institut Jules Bordet | PEARL | Trial closed | The PEARL study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women | accueil.oncologie@hubruxelles.be | 2 | 2 | |
| 22762 | Adjuvant. ECOG 0 or 1 | Thierry Berghmans | NSCLC | Merck | PEARLS | Trial closed for recruitment | A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) | 3 | 3 | ||
| 22638 | cN1/cT3-T4 | François-Xavier Otte | prostate | EORTC | Pegasus | Trial closed for recruitment | Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG. Pegasus | accueil.cons.radiotherapie@hubruxelles.be | 3 | 3 | |
| 22741 | Clinical/radiological evaluation compatible with stage III colon adenocarcinoma. No prior chemotherapy. |
Alain Hendlisz | Colon | Institut Jules Bordet | PePiTA | Trial closed | A BGDO study PePiTA trial : Preoperative chemosensitivity in adjuvant stage III colon cancer | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 22653 | HER 2 positive, first line | Philippe Aftimos | Breast | MedSir | PHERGain | Trial closed | Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 26122 | -DLBCL CD20 +de novo or transformed from low grade NHL or follicular lymphoma grade 3b -relapsed or refractory : Patients eligible for ASCT who failed to achieve a CR after at least one salvage therapy Or patients in first relapse after ASCT Or patients |
Marie Maerevoet | Multiple | LYSA LYmphoma | PIVeR | Trial closed | A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposide (PIVeR) | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22623 | brca 1/2 | Ahmad Hussein Awada | Multiple | PharmaMar | PM1183-B-005-14 | Trial closed | A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 2 | 2 | |
| 29673 | Nuria Kotecki | Multiple | PharmaMar | PM54-A-001-22 | Trial open for recruitment | Phase I/Ib, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM54 Administered Intravenously to Patients with Selected Advanced Solid Tumors | Nuria.Kotecki@hubruxelles.be | 1/1b | 1 | ||
| 22678 | Previously untreated patients with CD20-positive DLBCL - IPI score of 2-5 | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | POLARIX | Trial closed for recruitment | POLARIX - GO39942 - A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 22622 | ER+/HER2-. Adjuvant. End of hormonotherapy for pregnancy | Andrea Gombos | Breast | IBCSG | POSITIVE | Trial closed for recruitment | A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy | accueil.oncologie@hubruxelles.be | 3 | 3 |